Journal of Hematology & Oncology
Published: 04 September 2020
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19
"SARS-CoV-2 and its Spike protein directly stimulated platelets to facilitate the release of coagulation factors, the secretion of inflammatory factors, and the formation of leukocyte–platelet aggregates. Recombinant human ACE2 protein and anti-Spike monoclonal antibody could inhibit SARS-CoV-2 Spike protein-induced platelet activation.
Conclusions
Our findings uncovered a novel function of SARS-CoV-2 on platelet activation via binding of Spike to ACE2. SARS-CoV-2-induced platelet activation may participate in thrombus formation and inflammatory responses in COVID-19 patients."
The very real problem with viral vector vaccines is… genetic instructions are being given to an individual's own cells (via mRNA or DNA), so that their own cells produce COVID-19 spike proteins, the desired effect is that the individual's immune system then detects the spike proteins and produces antibodies against the spike protein, thus protecting the individual from infection with COVID-19, the above referenced research paper (published 09/04/2020) clearly describes the fact that in the interval of time between a viral vaccine being administered to an individual & that individual's immune system producing anti-spike protein antibodies, the risk of blood clot formation is significantly increased, this explains many of the deaths and injuries via stroke, heart attack, etc within a few days of receiving viral vector vaccines